Dermata Therapeutics (DRMA) Liabilities and Shareholders Equity (2020 - 2026)
Dermata Therapeutics (DRMA) posted quarterly Liabilities and Shareholders Equity of $7.5 million for Q1 2026, down 25.38% year-over-year from $10.0 million in Q1 2025, and down 5.06% quarter-over-quarter from $7.9 million in Q4 2025.
Dermata Therapeutics (DRMA) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
Dermata Therapeutics' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $7.5 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity fell 25.38% year-over-year to $7.5 million; the TTM figure through Mar 2026 stood at $27.0 million (up 6.2% YoY), while the FY2025 annual figure was $7.9 million, up 122.53% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $7.5 million, down from $7.9 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $11.0 million in Q2 2022, with the low at $3.5 million in Q4 2024.
- The 5-year median for Liabilities and Shareholders Equity is $7.5 million (2026), against an average of $7.5 million.
- The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity soared 869.9% in 2022, then slumped 55.71% in 2024.
- Dermata Therapeutics' Liabilities and Shareholders Equity stood at $6.9 million in 2022, then advanced by 14.89% to $8.0 million in 2023, then plunged by 55.71% to $3.5 million in 2024, then jumped by 122.53% to $7.9 million in 2025, then slipped by 5.06% to $7.5 million in 2026.
- Business Quant data shows DRMA's Liabilities and Shareholders Equity at $7.5 million in Q1 2026, $7.9 million in Q4 2025, and $5.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Dermata Therapeutics | 5.40 Mn | 5.40 Mn | - | 7.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.47 Mn |
| Dec 31, 2025 | 7.86 Mn |
| Sep 30, 2025 | 5.07 Mn |
| Jun 30, 2025 | 6.64 Mn |
| Mar 31, 2025 | 10.01 Mn |
| Dec 31, 2024 | 3.53 Mn |
| Sep 30, 2024 | 6.69 Mn |
| Jun 30, 2024 | 5.24 Mn |
| Mar 31, 2024 | 5.18 Mn |
| Dec 31, 2023 | 7.98 Mn |
| Sep 30, 2023 | 7.32 Mn |
| Jun 30, 2023 | 8.71 Mn |
| Mar 31, 2023 | 9.30 Mn |
| Dec 31, 2022 | 6.94 Mn |
| Sep 30, 2022 | 8.97 Mn |
| Jun 30, 2022 | 11.03 Mn |
| Mar 31, 2022 | 9.04 Mn |
| Dec 31, 2021 | 11.62 Mn |
| Sep 30, 2021 | 13.69 Mn |
| Jun 30, 2021 | 1.14 Mn |